Innovative Drug Platform Longevity Biotech's use of the Hybridtide peptide scaffold technology positions it at the forefront of developing long-acting oral therapeutics, creating opportunities for partnerships in drug delivery and specialty medication distribution.

Recent Funding & Grants The company secured a significant grant of over $316K from the National MS Society, indicating potential for additional research funding or collaboration opportunities in neurological and chronic disease treatments.

Target Disease Focus With programs aimed at multiple chronic diseases, especially multiple sclerosis, there is a potential market for clinical and research collaborations with healthcare providers, biotech firms, and pharma companies focusing on chronic illness therapeutics.

Growth & Revenue Operating with a revenue range of 1 to 10 million dollars and a small team, Longevity Biotech offers flexible partnership models for clinical development, licensing, and commercialization of innovative peptide-based drugs.

Technological Sophistication Utilizing advanced analytics tools like Google Analytics and Tag Manager, the company demonstrates a modern approach to research and digital engagement, providing opportunities for tech-enabled collaborations in data-driven drug development.